Georgia's Online Cancer Information Center

Find A Clinical Trial

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

Status
Closed
Cancer Type
Breast Cancer
Unknown Primary
Trial Phase
Phase I
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT04505826
Protocol IDs
OP-1250-001 (primary)
NCI-2020-13877
Study Sponsor
Olema Pharmaceuticals, Inc.

Summary

This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy
open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced
and/or metastatic hormone receptor (HR)-positive, her2-negative breast cancer.

Objectives

This is a Phase I dose escalation and dose expansion and Phase II monotherapy open--label,
first--in--human study to determine the dose limiting toxicity (DLT), maximum tolerated dose
(MTD) and/or recommended Phase II dose (RP2D), to characterize the safety and pharmacokinetic
(PK) profile, and to estimate the preliminary anti-tumor activity of OP-1250 as a single
agent in adult subjects with hormone receptor (HR)-positive/human epidermal growth factor
receptor 2 (HER2)-negative metastatic or locally advanced breast cancer. This study comprises
2 Phases: Phase I (Part A [Dose Escalation] and Part B [Dose Expansion]) and Phase II.
Additionally, all subjects (Phase I and Phase II) will be eligible to participate in 1 of 2
sub-studies. Patients must have received at least 1 prior hormonal regimen and at least 6
months of a prior continuous endocrine therapy for locally advanced or metastatic disease.
Patients will be evaluated for treatment emergent adverse events (AEs) during study
participation, and toxicity will be assessed according to the National Cancer Institute (NCI)
Common Terminology Criteria for Adverse Events, Version 5.0.

Eligibility

  1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  2. Must have received at least 1 prior hormonal regimen and at least 6 months of a prior continuous endocrine therapy for locally advanced or metastatic disease
  3. Must not have received prior oral endocrine therapy < 2 weeks prior to first dose
  4. Must not have received prior, chemotherapy in 2 weeks or within 5 half-lives whichever is earlier, antibody therapy within 4 weeks or investigational therapy within 4 weeks or 5 half-lives whichever is earlier, prior to the first dose
  5. Adequate hepatic function
  6. Adequate renal function
  7. Normal coagulation panel
  8. Willingness to use effective contraception
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.